Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stepwise Psychopharmacotherapy vs Antidepressant Monotherapy in Major Depressive Disorder
NCT06054321Recruiting
- Sponsor
- Chonnam National University Hospital
- Start
- Aug 2022
- Primary completion
- Dec 2028
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Randomised, open-label trial of Escitalopram oxalate oral solution, aripiprazole, lithium and mirtazapine in major depressive disorder (MDD) (4 arms), sponsored by Chonnam National University Hospital. Primary endpoint: Remission and treatment response status by Hamilton Depression Rating Scale at 1 year. Started Aug 2022; status: recruiting.
02
Drugs
Escitalopram oxalate oral solutionaripiprazolelithiummirtazapine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06054321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06054321.